Skip to main content

Remote Job Finders (RJF)

Phase III Fail Forces Neuphoria Into Strategic Review—With One Investor Offering a Takeover

Aside from offering to acquire all remaining shares of Neuphoria, existing investor Lynx1 Master Fund also announced its plan to nominate directors in the biotech’s upcoming board elections.

Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the third quarter, the pipeline-in-a-product strategy has never been more attractive.

How Effective Will TrumpRx and Other Direct-to-Consumer Drug Pricing Initiatives Be?

With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to patients. Analysts are skeptical that these efforts, including those announced to much fanfare from the White House, will result in meaningful reductions in drug spending.

Kezar Loses 70% of Staff After FDA Cancels Meeting on Autoimmune Asset

Kezar Life Sciences suffered multiple clinical holds and four patient deaths in a trial testing zetomipzomib for lupus—a program that has since been canned. The company is still pursuing development in autoimmune hepatitis, but recent FDA communications could delay its timeline.

Despite Obesity Drug Pricing Deal, GLP-1 Compounders Continue To Operate in the Shadows

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss drugs for patients, but knockoff versions of Zepbound and Wegovy still permeate the obesity market.
Scroll to top